Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749538 | 0.87 | ALDH1A1 (0.44) | POLBSMN1; SMN2TSHRALDH1A1HTT | |
| SCHEMBL6003121 | 0.84 | TSHR (0.53) | SMN1; SMN2TSHRUSP2ALDH1A1MEN1 | |
| SCHEMBL3982616 | 0.84 | TSHR (0.48) | POLBSMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL5146481 | 0.83 | TSHR (0.56) | SMN1; SMN2TSHRUSP2ALDH1A1MEN1 | |
| SCHEMBL6746141 | 0.83 | KMT2A (0.52) | POLBSMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL5656834 | 0.82 | APEX1 (0.43) | POLBSMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL14811167 | 0.81 | KMT2A (0.46) | TSHRHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL6749705 | 0.81 | ALDH1A1 (0.54) | POLBHSD17B10ALDH1A1PKMHTT | |
| SCHEMBL1855017 | 0.80 | KMT2A (0.51) | POLBSMN1; SMN2TSHRAPOBEC3GHSD17B10 | |
| SCHEMBL5657049 | 0.80 | L3MBTL1 (0.43) | POLBSMN1; SMN2TSHRCASP7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | disclosed |
| US-9856220-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2780324-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013068489-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6635637-B2 | Cyclic oxyguanidine derivatives useful as enzyme inhibitors, and particularly to a new class of non- peptidic inhibitors of proteolytic enzymes; treats pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema and inflammation | DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| EP-1307432-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002012207-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | POLB 1975/4885SMN1; SMN2 2880/4885TSHR 579/4885 |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | POLB 2984/4885SMN1; SMN2 1710/4885TSHR 473/4885 |
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | PDE3A, PDE5A, PDE3B | POLB 3001/4885SMN1; SMN2 1928/4885TSHR 420/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | POLB 2216/4885SMN1; SMN2 2899/4885TSHR 577/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | POLB 2218/4885SMN1; SMN2 3532/4885TSHR 685/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | POLB 1343/4885SMN1; SMN2 941/4885TSHR 2759/4885 |
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | PLG, TFPI, PLAT | POLB 2393/4885SMN1; SMN2 3440/4885TSHR 818/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | POLB 3008/4885SMN1; SMN2 1689/4885TSHR 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.